Search results
Showing 661 to 675 of 1070 results for drug therapy
Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.
Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults.
Permanent His-bundle pacemaker implantation for treating heart failure (HTG579)
Evidence-based recommendations on permanent His-bundle pacemaker implantation for treating heart failure. This involves attaching a wire connected to a pacemaker to the heart’s electrical conduction pathway (through a vein).
View recommendations for HTG579Show all sections
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.
Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause (TA1143)
Evidence-based recommendations on fezolinetant (Veoza) for treating moderate to severe vasomotor symptoms associated with menopause.
Show all sections
Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.
Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.
Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.
This guideline covers risk assessment, prevention and treatment in children, young people and adults at risk of, or who have, a pressure ulcer (also known as a bedsore or pressure sore). It aims to reduce the number of pressure ulcers in people admitted to secondary or tertiary care or receiving NHS care in other settings, such as primary and community care and emergency departments.
This guideline covers how organisations, practitioners and carers should work together to deliver high-quality care, stable placements and nurturing relationships for looked-after children and young people. It aims to help these children and young people reach their full potential and have the same opportunities as their peers.
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.